Home   >  
∨

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Angiogenesis/Protein Tyrosine Kinase

Chemical Structure Cat. No. Product Name CAS No.
BT44 Chemical Structure
 BCP48539 BT44 924759-42-2
BT44 is a novel RET agonist for the treatment of experimental neuropathies.
BI-4020 Chemical Structure
 BCP48204 BI-4020 2664214-60-0
BI-4020 is a fourth-generation, non-covalent, and orally active inhibitor of EGFR tyrosine kinase.
Almonertinib mesylate Chemical Structure
 BCP48089 Almonertinib mesylate 2134096-06-1
Almonertinibmesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations.
PHD-1-IN-1 Chemical Structure
 BCP47256 PHD-1-IN-1 2009343-14-8
PHD-1-IN-1 is a potent inhibitor of hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme(IC50 = 0.034 μM).
GDC-0214 Chemical Structure
 BCP47996 GDC-0214 1831144-46-7
GDC0214 is a potent, selective inhalable and lung-restricted inhibitor of JAK1 with IC50 of 8.52 nM, displays 6.3/704/28 fold selectivity over JAK2/JAK3/TYK2.
JAK-IN-5 hydrochloride Chemical Structure
 BCP48031 JAK-IN-5 hydrochloride 2751323-21-2
JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
PLN-1474 Chemical Structure
 BCP47995 PLN-1474 2408065-32-5
PLN-1474 is a small molecule, orally available, selective inhibitor of integrin alphaVbeta1 (αVβ1).
GNF2133 HCl Chemical Structure
 BCP45493 GNF2133 HCl 2561414-57-9
GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively.
Fosgonimeton Chemical Structure
 BCP46997 Fosgonimeton 2093305-05-4
Fosgonimeton is a hepatocyte growth factor receptor agonist.
SJ10542 Chemical Structure
 BCP46974 SJ10542 SJ10542
SJ10542 is JAK2/3 PROTAC. SJ10542 displayed high selectivity over GSPT1 and other members of the JAK family and potency in patient-derived ALL cells containing both JAK2 fusions and CRLF2 rearrangements.
123下一页末页共 853 条记录 1 / 86 页 
0086-13720134139